Genasense Injection To Go Before ODAC
This article was originally published in The Pink Sheet Daily
Executive Summary
Genta's chronic lymphocytic leukemia treatment Genasense will be reviewed by FDA's Oncology Drugs Advisory Committee Sept. 6, the firm said July 27
You may also be interested in...
ODAC To Review Pfizer’s Fragmin, Genta’s Genasense, Abraxis Bioscience’s Abraxane
The three products will be reviewed by the FDA advisory committee Sept. 6-7.
ODAC To Review Pfizer’s Fragmin, Genta’s Genasense, Abraxis Bioscience’s Abraxane
The three products will be reviewed by the FDA advisory committee Sept. 6-7.
Genta Plans Genasense Confirmatory Trial In Treatment-Naive Patients
With approval possible in June for relapsed or refractory leukemia, Genta is seeking a marketing partner for oblimersen.